Laurus Labs Ltd (NSE: LAURUSLABS) and Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA) are both listed in the Medicinal Chemicals and Botanical Products industry. Laurus Labs has a market capitalisation of ₹1,26,865 Cr and Sun Pharmaceutical Industries ₹4,24,682 Cr, as of 9 Nov 2026. Their P/E ratios are 142.7 and 37 respectively. Return on equity is 17.74% for Laurus Labs and 14.72% for Sun Pharmaceutical Industries. Over one year, Laurus Labs's share price is up 151.6% and Sun Pharmaceutical Industries's is up 11.6%.
| Metric | Laurus Labs | Sun Pharmaceutical Industries |
|---|---|---|
| NSE Symbol | LAURUSLABS | SUNPHARMA |
| BSE Code | 540222 | 524715 |
| Share Price | ₹2,454.00 | ₹1,909.20 |
| Market Cap | ₹1,26,865 Cr | ₹4,24,682 Cr |
| P/E Ratio | 142.7 | 37 |
| Return on Equity | 17.74% | 14.72% |
| Return on Assets | 8.18% | 8.47% |
| Dividend Yield | 0.10% | 0.56% |
| Beta (1Y) | 0.47 | -0.15 |
| 1-Year Price Change | +151.6% | +11.6% |
| 3-Month Price Change | +32.4% | -2.1% |
| 52-Week Range | ₹944.90 – ₹2,480.00 | ₹1,583.70 – ₹2,046.90 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹2,206 Cr | ₹16,199 Cr |
| Quarterly Net Profit | ₹436 Cr | ₹1,995 Cr |
| Net Margin | 19.8% | 12.3% |
| EPS (Basic, Quarter) | ₹8.17 | ₹8.30 |
| Results Basis | consolidated | consolidated |
| Headquarters | Hyderabad, Telangana | Mumbai, Maharashtra |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. In addition, the company develops novel enzymatic solutions fo…
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, urology, dermatology, respiratory, dental, and nutritionals. It also provides g…
Sun Pharmaceutical Industries has a market capitalisation of ₹4,24,682 Cr, against ₹1,26,865 Cr for Laurus Labs as of 9 Nov 2026, about 3.3 times the size by market cap.
Laurus Labs has a P/E of 142.7 and Sun Pharmaceutical Industries a P/E of 37 as of 9 Nov 2026.
Laurus Labs has a return on equity of 17.74% and Sun Pharmaceutical Industries 14.72%.
Laurus Labs's share price is up 151.6% over one year and Sun Pharmaceutical Industries's is up 11.6%.
Laurus Labs reported revenue of ₹2,206 Cr and net profit of ₹436 Cr for Q2 FY27. Sun Pharmaceutical Industries reported revenue of ₹16,199 Cr and net profit of ₹1,995 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.